MxB Disrupts Hepatitis C Virus NS5A-CypA Complex: Insights From a Combined Theoretical and Experimental Approach.

CypA HCV MxB NS5A host antiviral innate immunity protein-protein interaction

Journal

Frontiers in microbiology
ISSN: 1664-302X
Titre abrégé: Front Microbiol
Pays: Switzerland
ID NLM: 101548977

Informations de publication

Date de publication:
2022
Historique:
received: 05 01 2022
accepted: 08 02 2022
entrez: 4 4 2022
pubmed: 5 4 2022
medline: 5 4 2022
Statut: epublish

Résumé

The human myxovirus resistance B (MxB) protein is an interferon-induced restriction factor that fights a wide range of viruses. We previously demonstrated that MxB binds to hepatitis C virus (HCV)-encoded non-structural protein 5A (NS5A) and inhibits HCV infection by impairing the formation of cyclophilin A (CypA)-NS5A complex. However, the molecular details about how the presence of MxB diminishes the binding of NS5A to CypA remain uncovered. In this study, through molecular dynamic simulations and biochemical assays, we characterized that MxB binds to NS5A domain I through its N-terminal and GTPase domains. Specifically, amino acids (aa.) 189-191 and aa. 330-334 within MxB, together with NS5A residues aa. 71-73, are crucial for MxB-NS5A interaction. Furthermore, we predicted the CypA:NS5A and CypA:NS5A:MxB complexes and calculated the per-residue energy decomposition for identified key residues of the CypA-NS5A interface. A 28% decrease in CypA-NS5A binding affinity was observed in the presence of MxB, suggesting a weakened CypA-NS5A association upon binding of MxB to NS5A, which may contribute to the MxB-mediated inhibitory effect on the formation of CypA-NS5A complex. This work provides information for the antiviral mechanism of MxB and may facilitate the discovery of new strategies to combat CypA-dependent viruses.

Identifiants

pubmed: 35369502
doi: 10.3389/fmicb.2022.849084
pmc: PMC8969595
doi:

Types de publication

Journal Article

Langues

eng

Pagination

849084

Informations de copyright

Copyright © 2022 Li, An, Yin, Zhang, Shao, Yi and Cen.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Sci Adv. 2017 Sep 15;3(9):e1701264
pubmed: 28929138
J Biol Chem. 2009 Jun 19;284(25):16998-17005
pubmed: 19380579
Nature. 2013 Oct 24;502(7472):559-62
pubmed: 24048477
Antimicrob Agents Chemother. 2012 Jul;56(7):3888-97
pubmed: 22585215
J Biol Chem. 1996 Sep 20;271(38):23478-86
pubmed: 8798556
Cell Host Microbe. 2013 Oct 16;14(4):371-3
pubmed: 24139395
Cells. 2019 Apr 25;8(4):
pubmed: 31027278
J Virol. 2018 Dec 10;93(1):
pubmed: 30333168
Virology. 2002 Jan 20;292(2):198-210
pubmed: 11878923
J Mol Graph Model. 2004 May;22(5):377-95
pubmed: 15099834
Nucleic Acids Res. 2015 Jul 1;43(W1):W174-81
pubmed: 25883148
Cell Host Microbe. 2014 Nov 12;16(5):627-638
pubmed: 25312384
Cell Host Microbe. 2013 Oct 16;14(4):398-410
pubmed: 24055605
J Virol. 2009 Jul;83(13):6554-65
pubmed: 19386705
Emerg Microbes Infect. 2020 Dec;9(1):2030-2045
pubmed: 32873191
J Virol. 2008 Jun;82(11):5269-78
pubmed: 18385230
Bioinformatics. 2015 Oct 15;31(20):3359-61
pubmed: 26069263
ACS Infect Dis. 2016 Nov 11;2(11):839-851
pubmed: 27676132
J Virol. 2012 May;86(9):4811-22
pubmed: 22345441
Nat Protoc. 2010 Apr;5(4):725-38
pubmed: 20360767
Proteins. 2003 Jul 1;52(1):80-7
pubmed: 12784371
J Virol Methods. 2010 May;165(2):202-10
pubmed: 20132841
J Virol. 2020 Oct 27;94(22):
pubmed: 32907985
J Biol Chem. 2011 Jun 10;286(23):20441-54
pubmed: 21489988
J Biol Chem. 2004 Nov 19;279(47):48576-87
pubmed: 15339921
Acta Crystallogr D Biol Crystallogr. 2013 Jun;69(Pt 6):1115-23
pubmed: 23695256
J Virol. 2014 Aug;88(16):9017-26
pubmed: 24899177
Nat Commun. 2018 May 17;9(1):1980
pubmed: 29773792
J Virol. 2011 Jul;85(14):7460-4
pubmed: 21593166
Nature. 2013 Oct 24;502(7472):563-6
pubmed: 24121441
Acta Pharm Sin B. 2021 Jun;11(6):1555-1567
pubmed: 33614402
J Chem Inf Model. 2011 Jan 24;51(1):69-82
pubmed: 21117705
J Biol Chem. 2005 Jun 10;280(23):21965-71
pubmed: 15772070
Proteins. 2003 Nov 15;53(3):693-707
pubmed: 14579360
Nucleic Acids Res. 2007;35(10):3375-82
pubmed: 17478507
Nat Protoc. 2010 May;5(5):883-97
pubmed: 20431534
J Biol Chem. 2009 May 15;284(20):13589-13601
pubmed: 19297321
PLoS Pathog. 2010 Sep 23;6(9):e1001118
pubmed: 20886100
J Am Chem Soc. 2003 Feb 19;125(7):1731-7
pubmed: 12580598
Proteins. 2010 Jun;78(8):1950-8
pubmed: 20408171
J Hepatol. 2010 Jul;53(1):50-6
pubmed: 20451281

Auteurs

Quanjie Li (Q)

Department of Immunology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, Beijing, China.

Ni An (N)

Department of Immunology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, Beijing, China.

Xiao Yin (X)

Department of Immunology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, Beijing, China.
Center for Drug Evaluation, National Medical Products Administration, Beijing, China.

Ruixin Zhang (R)

Department of Immunology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, Beijing, China.

Huihan Shao (H)

Department of Immunology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, Beijing, China.

Dongrong Yi (D)

Department of Immunology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, Beijing, China.

Shan Cen (S)

Department of Immunology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, Beijing, China.

Classifications MeSH